Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
ISIN : BRM1RNBDR006
Share Class Description:
BSP:M1RN34: BRDRCompare
Compare
Traded in other countries / regions
MRNA.USAM1RN34.Brazil0A45.UK0QF.Germany1MRNA.ItalyMRNA.MexicoMRNA.AustriaMRNA.PeruMRNA_KZ.Kazakhstan IPO Date
2020-10-13Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.92 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 6.37 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 190.8 | |||||
| 3-Year EBITDA Growth Rate | -64.8 | |||||
| 3-Year EPS without NRI Growth Rate | -83.9 | |||||
| 3-Year Book Growth Rate | 78.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -51.12 | |||||
| Future 3-5Y Total Revenue Growth Rate | -24.82 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.64 | |||||
| 9-Day RSI | 51.93 | |||||
| 14-Day RSI | 53.74 | |||||
| 6-1 Month Momentum % | 18.73 | |||||
| 12-1 Month Momentum % | -27.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.42 | |||||
| Quick Ratio | 3.36 | |||||
| Cash Ratio | 2.85 | |||||
| Days Inventory | 47.99 | |||||
| Days Sales Outstanding | 59.32 | |||||
| Days Payable | 34.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.4 | |||||
| Shareholder Yield % | 2.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 30.52 | |||||
| Operating Margin % | -62.76 | |||||
| Net Margin % | -69.8 | |||||
| FCF Margin % | -56.86 | |||||
| ROE % | -28.66 | |||||
| ROA % | -21.48 | |||||
| ROIC % | -41.33 | |||||
| ROC (Joel Greenblatt) % | -161.87 | |||||
| ROCE % | -21.5 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.94 | |||||
| PB Ratio | 2.85 | |||||
| Price-to-Tangible-Book | 2.87 | |||||
| EV-to-EBIT | -8.26 | |||||
| EV-to-Forward-EBIT | -10.15 | |||||
| EV-to-EBITDA | -9.82 | |||||
| EV-to-Forward-EBITDA | -11.12 | |||||
| EV-to-Revenue | 4.77 | |||||
| EV-to-Forward-Revenue | 7.45 | |||||
| EV-to-FCF | -8.43 | |||||
| Price-to-Projected-FCF | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 6.87 | |||||
| Price-to-Net-Cash | 9.8 | |||||
| Earnings Yield (Greenblatt) % | -12.11 | |||||
| FCF Yield % | -9.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moderna Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 33,715.77 | ||
| EPS (TTM) (R$) | -3.048 | ||
| Beta | -0.32 | ||
| Volatility % | 47 | ||
| 14-Day RSI | 53.74 | ||
| 14-Day ATR (R$) | 1.107211 | ||
| 20-Day SMA (R$) | 26.714 | ||
| 12-1 Month Momentum % | -27.56 | ||
| 52-Week Range (R$) | 16.7 - 36.5 | ||
| Shares Outstanding (Mil) | 7,657.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moderna Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moderna Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Moderna Inc Frequently Asked Questions
What is Moderna Inc(BSP:M1RN34)'s stock price today?
The current price of BSP:M1RN34 is R$26.94. The 52 week high of BSP:M1RN34 is R$36.50 and 52 week low is R$16.70.
When is next earnings date of Moderna Inc(BSP:M1RN34)?
The next earnings date of Moderna Inc(BSP:M1RN34) is 2024-05-03 Est..
Does Moderna Inc(BSP:M1RN34) pay dividends? If so, how much?
Moderna Inc(BSP:M1RN34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers